---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-25-000014"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:45:42.731495+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026

## Summary
- Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.
- Net loss for Q4 2024 was $16.0M, compared to $19.4M in Q4 2023; FY2024 net loss $69.7M vs $82.4M.
- R&D expenses decreased to $12.3M in Q4 2024 from $15.3M in Q4 2023; FY2024 R&D $51.3M vs $59.4M.
- Initial Phase 2 data for BDTX-1535 in newly diagnosed non-classical EGFRm NSCLC expected Q2 2025.
- Cash runway expected into Q4 2026; management to seek FDA feedback on registrational path for BDTX-1535 in H2 2025.

## SEC filing metadata
- accession: 0001701541-25-000014
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000014/0001701541-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000014/bdtx-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-25-000014
- JSON: https://secwatch.observer/filing/0001701541-25-000014.json
- Plain text: https://secwatch.observer/filing/0001701541-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.